MedGenesis Therapeutix Inc.

MedGenesis Therapeutix (MedGenesis) is a privately-held biopharmaceutical company committed to developing and commercializing highly innovative treatments for patients with serious neurologic disease. MedGenesis' lead program, glial cell-line derived neurotrophic factor (GDNF), is a potentially disease-modifying treatment for Parkinson's disease that has recently completed Phase 2 clinical studies. The program is the first to use MedGenesis' proprietary intermittent convection-enhanced delivery (CED) paradigm for targeted, local drug administration to the affected brain area.

MedGenesis Therapeutix Inc.


What's New

Parkinson's in the News: Pfizer ends research for new Alzheimer's, Parkinson's drugs

11-Feb-2018: MedGenesis Therapeutix Announces Termination of GDNF Option Agreement with Pfizer Inc.

1-Sep-2017: MedGenesis Therapeutix Announces Successful National Scientific Advice Meetings for GDNF in Parkinson's Disease